ALX Oncology Inc. (ALXO)
ALX Oncology Statistics
Share Statistics
ALX Oncology has 53.38M shares outstanding. The number of shares has increased by 5.17% in one year.
| Shares Outstanding | 53.38M |
| Shares Change (YoY) | 5.17% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 77.92% |
| Shares Floating | 34.04M |
| Failed to Deliver (FTD) Shares | 99 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 7.83M, so 14.85% of the outstanding shares have been sold short.
| Short Interest | 7.83M |
| Short % of Shares Out | 14.85% |
| Short % of Float | 25.43% |
| Short Ratio (days to cover) | 6.81 |
Valuation Ratios
The PE ratio is -0.65 and the forward PE ratio is -0.73. ALX Oncology's PEG ratio is 0.02.
| PE Ratio | -0.65 |
| Forward PE | -0.73 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 0.77 |
| P/FCF Ratio | -0.71 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ALX Oncology Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.
| Current Ratio | 7.26 |
| Quick Ratio | 7.26 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.38 |
| Cash Flow / Debt | -280.26 |
| Interest Coverage | -82.4 |
Financial Efficiency
Return on equity (ROE) is -1.19% and return on capital (ROIC) is -124.91%.
| Return on Equity (ROE) | -1.19% |
| Return on Assets (ROA) | -0.91% |
| Return on Capital (ROIC) | -124.91% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,685,625 |
| Employee Count | 80 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -92.41% in the last 52 weeks. The beta is 1.01, so ALX Oncology's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -92.41% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 3.09 |
| Relative Strength Index (RSI) | 41.2 |
| Average Volume (20 Days) | 1.26M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -142.47M |
| Net Income | -134.85M |
| EBITDA | -132.25M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.58 |
Balance Sheet
The company has 17.57M in cash and 435K in debt, giving a net cash position of 17.13M.
| Cash & Cash Equivalents | 17.57M |
| Total Debt | 435K |
| Net Cash | 17.13M |
| Retained Earnings | -621.12M |
| Total Assets | 147.78M |
| Working Capital | 115.85M |
Cash Flow
In the last 12 months, operating cash flow was -121.91M and capital expenditures -447K, giving a free cash flow of -122.36M.
| Operating Cash Flow | -121.91M |
| Capital Expenditures | -447K |
| Free Cash Flow | -122.36M |
| FCF Per Share | -2.35 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ALXO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -293.18% |
| FCF Yield | -260.46% |
Analyst Forecast
The average price target for ALXO is $3, which is 240.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 240.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -7 |
| Piotroski F-Score | 3 |